Suven Life Sciences Share Price

₹ 267.50

+₹8.65 (3.34%)
1D
Last updated 02 Nov, 2026, 14:06 IST
NSE: SUVEN
|
Pharmaceuticals

Suven Life Sciences Share Price Today

As of 2 Nov 2026, Suven Life Sciences share price is ₹267.50. The stock opened at ₹260.10, compared to its previous close of ₹258.85. During today's trading session, Suven Life Sciences share price moved in the range of ₹256.30 to ₹268.20, with an average price of ₹262.25 for the day. Looking at its last 52-week, the stock has touched a low of ₹124.11 and a high of ₹403.35. On the performance front, Suven Life Sciences share price has increased by 22.17% over the last six months and is up 34.47% on a year-on-year basis.

Share price over the last 1 day rose from 259.35 to 268.00, ranging between 256.45 and 268.00.
₹256.30
3.34% up today
₹268.20
1D LOW
1D HIGH

Suven Life Sciences Stock Insights

Latest Earning
Op Profit TrendDown by 179.85% QoQ
Latest Earning
Net Profit TrendDown by 179.85% QoQ
Latest Earning
Revenue TrendUp by 33.61% QoQ
Stock Performance
OutperformingBeat Nifty by 26.28 % in last 6 month
Shareholding Pattern
DIIDII decreased stake by 23.13%
Shareholding Pattern
FIIFII decreased stake by 4.42%
Suven Life Sciences stock performance
Open₹260.10
High₹268.20
Low₹256.30
Prev. close₹258.85
Suven Life Sciences trading activity
Volume2,41,744
Average traded price₹262.70
Last traded time02:06:18 02 Nov
Last traded quantity1
Circuit
L
H
₹207.10
₹310.60
52-week
L
H
₹124.11
₹403.35
Mkt Cap Cr
7,292.94
P/E
-20.7
P/B
10.65
ROA
-56.46%
ROE
-46.73%
ROCE
-45.42%
Quick Ratio
29.15
EV/EBITDA
-20.25

Based on fundamentals, this stock's

Performance: 1 out of 5, Very Poor
Performance
Very Poor
Suven Life Scie. has not beaten FD return of 7%
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Suven Life Scie. appears overvalued compared to its peers
Earnings: 3 out of 5, Neutral
Earnings
Neutral
Suven Life Scie. earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Apollo Hospitals1,20,779.1155.6112.749.79%20.48%17.27%0.9830.42
MANIPAL HEALTH ENTERPRI L87,926.3997.025.354.07%10.59%9.51%1.1734.66
Max Healthcare83,704.6860.657.397.37%12.18%13.24%0.8433.68
Aster DM Healthcare59,570.09164.2814.164.47%8.48%10.1%1.966.59
Fortis Healthcare58,116.6854.295.876.7%10.53%12.56%0.828.03
Narayana Hrudayalaya35,143.9343.047.746.43%17.17%12.26%2.0719.68
Global Health34,121.9061.788.619.35%14.05%15.26%2.5432.32
Dr. Lal Path Labs31,997.0258.5712.7617.36%20.13%25.56%3.3834.28
KRISHNA INST OF MED SCI L29,480.26151.67.872.51%10.74%7.99%0.6839.1
Syngene International16,251.7287.333.342.79%5.47%7.06%1.2922.34

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Suven Life Sciences Company Background

ISIN
INE495B01038
Sector Market Cap
₹ 7,292.94 Cr

Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).

Suven Life Sciences Financial Highlights

  • Revenue: Suven Life Sciences reported revenue of ₹21.04 crore in FY26 vs ₹17.56 crore in FY25. It showed an increase of 19.82% on a yearly basis.
  • Operating Profit: Suven Life Sciences reported an operating loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a year-on-year basis.
  • Net Profit: Suven Life Sciences reported a net loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a yearly basis.

Suven Life Sciences Quarterly Result Highlights

  • Suven Life Sciences reported revenue of ₹11.09 crore in Jun 2026, compared with ₹8.30 crore in Mar 2026, representing an increase of 33.61% on a quarter-on-quarter (QoQ) basis.
  • Suven Life Sciences reported an operating loss of ₹127.61 crore in Jun 2026, compared with ₹45.60 crore in Mar 2026, representing a decrease of 179.85% on a quarter-on-quarter (QoQ) basis.
  • Suven Life Sciences reported a loss of ₹127.61 crore in Jun 2026, compared with ₹45.60 crore in Mar 2026, reflecting a decrease of 179.85% on a QoQ basis.
  • The earnings per share (EPS) of Suven Life Sciences stood at ₹12.13 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
65.47%
FII
0.46%
Other DII
2.09%
Retail and other
31.90%
Mutual funds
0.08%
Foreign Institutional Investor (FII)
FII shareholding by period
Jun 20260.57%
Jul 20260.48%
Aug 20260.48%
Sep 20260.46%

Suven Life Sciences Investment Returns

1 day
-2.02%
1 week
-0.96%
1 month
-19.16%
1 year
+34.47%
3 years
+242.85%
5 years
+168.94%

Suven Life Sciences Share Price History

Suven Life Sciences share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
30 Oct 26
₹263.50 / ₹258.85
-2.02%
29 Oct 26
₹269.90 / ₹264.20
-1.44%
28 Oct 26
₹261.40 / ₹268.05
+2.54%
27 Oct 26
₹262.00 / ₹261.40
-0.23%
Show more

Suven Life Sciences Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹7.11₹6.66₹11.69₹13.54
Other Income₹13.93₹10.90₹21.13₹8.45
Total Revenue₹21.04₹17.55₹32.82₹21.99
Total Expenses₹297.39₹178.30₹146.36₹146.26
Profit Before Tax-₹276.34-₹160.75-₹106.08-₹118.27
Tax₹0.00₹0.00-₹1.00₹0.00
Profit After Tax-₹276.34-₹160.75-₹105.08-₹118.27
EPS - Basic-₹12.13-₹7.37-₹4.82-₹5.42
EPS - Diluted-₹12.13-₹7.37-₹4.82-₹5.42

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹276.34-₹160.75-₹106.08-₹118.27
Income before WC changes-₹282.33-₹164.77-₹128.54-₹126.36
Change in Assets-₹8.79-₹0.92₹4.78₹8.01
Change in Liabilities-₹9.54₹10.98₹2.11₹3.47
Change in WC-₹18.33₹10.07₹6.89₹11.48
Cash flow from Operations-₹299.90-₹155.31-₹115.47-₹115.98
Cash flow from Investing-₹462.11₹154.95₹94.44-₹247.81
Cash flow from Financing₹756.78-₹0.76-₹1.05₹395.54
Total Cash Flow-₹5.23-₹1.12-₹22.09₹31.75
Cash (Start of the year)₹15.03₹14.93₹37.02₹5.27
Cash (End of the year)₹9.80₹13.82₹14.93₹37.02

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹77.51₹59.71₹28.23₹137.32
Current Assets₹546.71₹75.47₹256.67₹251.59
Total Assets₹624.21₹135.18₹284.90₹388.91
Current Liabilities₹18.75₹23.49₹13.52₹11.13
Net Current Asset₹527.96₹51.99₹243.16₹240.46
Non-Current Liabilities₹14.06₹1.71₹1.35₹2.46
Equity Capital₹591.40₹109.99₹270.04₹375.32
Total Equity & Liabilities₹624.21₹135.18₹284.90₹388.91

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹7.11₹6.66₹11.69₹13.54
Other Income₹13.91₹10.73₹21.13₹8.45
Total Revenue₹21.03₹17.38₹32.82₹21.99
Total Expenses₹75.89₹64.46₹49.29₹48.12
Profit Before Tax-₹54.86-₹47.08-₹9.01-₹20.13
Tax₹0.00₹0.00-₹1.00₹0.00
Profit After Tax-₹54.86-₹47.08-₹8.01-₹20.13
EPS - Basic-₹2.41-₹2.16-₹0.37-₹1.13
EPS - Diluted-₹2.41-₹2.16-₹0.37-₹1.13

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹54.86-₹47.08-₹9.01-₹20.13
Income before WC changes-₹60.84-₹51.00-₹31.47-₹28.22
Change in Assets-₹8.79-₹0.92₹4.78₹8.01
Change in Liabilities₹1.16₹3.92-₹0.06-₹1.61
Change in WC-₹7.63₹3.00₹4.73₹6.40
Cash flow from Operations-₹67.71-₹48.60-₹20.56-₹22.92
Cash flow from Investing-₹685.74₹44.21-₹0.68-₹348.82
Cash flow from Financing₹756.78-₹0.76-₹1.05₹395.54
Total Cash Flow₹3.34-₹5.15-₹22.30₹23.79
Cash (Start of the year)₹0.46₹4.40₹26.70₹2.90
Cash (End of the year)₹3.80-₹0.75₹4.40₹26.70

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹990.35₹751.18₹605.34₹619.18
Current Assets₹540.71₹57.71₹246.14₹241.26
Total Assets₹1,531.06₹808.89₹851.48₹860.44
Current Liabilities₹13.63₹7.67₹4.76₹4.54
Net Current Asset₹527.08₹50.04₹241.38₹236.73
Non-Current Liabilities₹14.06₹1.71₹1.35₹2.46
Equity Capital₹1,503.37₹799.51₹845.38₹853.44
Total Equity & Liabilities₹1,531.06₹808.89₹851.48₹860.44
* All values are in INR Crore
Suven Life Sciences market depth
Bid quantityBid priceAsk priceAsk quantity
24267.5267.61
24267.45267.651
25267.4267.719
60267.35267.7537
57267.3267.870
Total bid quantity190
Total ask quantity128
Suven Life Sciences technical summary
Bearish indicators3
Neutral indicators2
Bullish indicators3
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
29.92
Bearish
ATR (14)
13.46
Neutral
STOCH(9,6)
4.71
Bullish
STOCH RSI (14)
14.08
Bullish
ADX(9)
34.87
Bearish
UO(9)
33.1
Neutral
ROC(12)
-8.78
Bearish
WillR(14)
-95.86
Bullish
Period
Simple value
Exponential vaue
5D
262.9
264.01
10D
271.63
270.58
20D
283.64
284.27
50D
326.48
305.34
100D
316.9
298.84
Volume trend — traded volume by day
2 Nov2L
30 Oct2L
29 Oct2L
28 Oct4L
27 Oct2L
26 Oct6L
Average3L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Suven Life Sciences
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Suven Life Sciences

Fund name
AUM
Quant Small Cap Fund
0.25%
Bandhan BSE Healthcare Index Fund
0.07%
Motilal Oswal BSE 1000 Index Fund
0.00%

Suven Life Sciences Returns Calculator

Top Gainers

ITI Share Price
₹259.14
+43.19 (+20%)
ENGINERSIN Share Price
₹291.50
+39.65 (+15.74%)
PRAJIND Share Price
₹269.87
+28.17 (+11.65%)
DIXON Share Price
₹12280.00
+1280 (+11.64%)
MSUMI Share Price
₹39.05
+3.91 (+11.13%)
See more

Top Losers

INDIGOPNTS Share Price
₹880.00
-117.3 (-11.76%)
CLEAN Share Price
₹665.85
-49.75 (-6.95%)
ZEEL Share Price
₹61.97
-4.43 (-6.67%)
POLICYBZR Share Price
₹934.00
-66.1 (-6.61%)
SYRMA Share Price
₹1528.30
-97 (-5.97%)
See more

Suven Life Sciences Share Price FAQs

Please be aware that Suven Life Sciences stock prices are subject to continuous fluctuations due to various factors.